3.8 Review

Parkinson's disease psychosis: presentation, diagnosis and management

Journal

NEURODEGENERATIVE DISEASE MANAGEMENT
Volume 7, Issue 6, Pages 365-376

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/nmt-2017-0028

Keywords

antipsychotic; delusions; hallucinations; Parkinson's disease; pimavanserin; psychosis

Funding

  1. Michael J Fox Foundation
  2. Massachusetts General Hospital
  3. Biohaven Pharmaceuticals
  4. Empire Clinical Research Investigator Program (ECRIP)
  5. New York State Department of Health
  6. National Parkinson Foundation
  7. NIH (NINDS)

Ask authors/readers for more resources

Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor symptoms. Psychosis is a common feature of Parkinson's disease. Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions. PDP is associated with reduced function and quality of life. The initial management approach should focus on identification and treatment of any contributory medical factors, reduction or discontinuation of medications with potential to induce or worsen psychosis, nonpharmacological strategies and consideration of acetylcholinesterase inhibitor treatment in the setting of dementia. Pimavanserin, quetiapine and clozapine may all be considered for use in PDP. In this review, we discuss the presentation, diagnosis and management of PDP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available